Women's Health: Recent Episodes
ReachMD
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Sawsan As-Sanie, MD
Guest: Linda Bradley, MD
Endometriosis is often called a public health crisis for women. The delay in diagnosis can be greater than 10 years, during which time women suffer many physical and psychosocial issues that negatively impact their quality of life. Join Drs. Lee Shulman, Sawsan As-Sanie, and Linda Bradley as they identify strategies to overcome the diagnostic delay and its associated consequences.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG
While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient’s outcomes. Under what circumstances should you consider using a GnRH antagonist either before or after conservative surgery? Join Drs. Lee Shulman, Ayman Al-Hendy, and James Simon as they provide their collective thoughts on how best to sequence a GnRH antagonist with conservative surgery when managing endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Guest: Sawsan As-Sanie, MD
GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agonists. Join Drs. Lee Shulman, Ayman Al-Hendy, and Sawsan As-Sanie as they discuss the estrogen threshold hypothesis from the perspective of GnRH antagonists and delve into clinical data supporting the use of GnRH antagonists in the medical management of endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. Join Drs. Lee Shulman, Melissa Simon, and Linda Bradley as they discuss how to utilize the SF-36 and EHP-30 questionnaires in clinical practice and explore strategies to facilitate patient-healthcare provider discussions to improve overall short- and long-term patient outcomes.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Guest: Melissa Simon, MD
Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Shulman, Linda Bradley, and Melissa Simon as they address these issues to help facilitate a patient-centered practice environment for all patients.
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.
Host: Anita L. Nelson, MD
Guest: Barbara Dehn, Np, FAANP, NCMP
Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Jeremy Force
Get up to date on how APPs can optimize care for patients with HER2-positive breast cancer in this on-demand webcast capturing a live presentation by Dr Jeremy Force.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD
The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael K. Georgieff, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Arjeme Denise Cavens, MD
Guest: Lee Shulman MD, FACOG, FACMG
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Arjeme Denise Cavens, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Malcolm G. Munro MD, FRCS(c), FACOG
Guest: Michael Auerbach, MD
This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.
Host: Helena Yu, MD
Guest: Makenzi Evangelist, MD
This Expert Exchange webcast is designed to enhance clinicians’ awareness of the function and role of HER3 in emerging treatment strategies for non-small cell lung cancer and metastatic breast cancer.
Host: Charles P. Vega, MD
Guest: George Grossberg, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to treat agitation in patients with Alzheimer’s dementia.
Host: Charles P. Vega, MD
Guest: Thomas W. Heinrich, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to define, identify and assess agitation in Alzheimer’s dementia.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Alexandra Benachi, MD, PhD
Guest: Julien Zuber, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
There exists a long-standing controversy about drawing parallels between transplant and pregnancy immunology. Listen in as Drs. Alexandra Benachi, Julien Zuber, and Lee Shulman discuss why these considerations are so important for you and your colleagues, patients, and their families to understand. Discover how links between kidney transplantation and maternal anti-fetal rejection may impact your practice and spark new pathways in medicine.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Masja de Haas, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?
Host: Anita H. Clayton, MD
Guest: Jennifer L. Payne, MD
This animated Women’s Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?
Host: Jennifer L. Payne, MD
Optimizing the management of comorbid depression and menopause is a significant clinical challenge. When the darkness begins to set in, are you able to hear your patients’ needs and deliver life-changing treatment?
Join Dr. Jennifer Payne as she provides concrete tips and explores the latest guidelines and research on therapies that improve vasomotor symptoms, mood, and perimenopausal depression. Get ready to offer new hope to your patients as you help them cool off and begin to see the dawn of a new day.
Host: Michael Krychman, MD
For affected women, acute vulvovaginal candidiasis (VVC) brings with it a significant health burden, and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved diagnosis, management, and quality of care. Join Dr. Michael Krychman as he dissects the barriers to managing VVC and RVVC and provides insights on diagnosis and management based on guidelines, plus an overview of innovative therapeutic agents. The unique qualities of the current and emerging therapeutic interventions may well represent a significant step forward in how you manage these challenging infections.
Host: Andrew M. Kaunitz, MD, FACOG
By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.
Host: Hugh S. Taylor, MD
Endometriosis is challenging to diagnose, with approximately 6 to 11 years from symptom onset to definitive diagnosis and treatment. Many medical providers are not adequately familiar with the disease, and this, coupled with historically limited medical options, has resulted in surgical approaches often being considered as the first treatment option. Join us as Dr. Hugh Taylor discusses how this landscape is changing to one in which safe and effective medical options can now offer improved outcomes for our patients with endometriosis.
Host: David L. Eisenberg, MD, MPH, FACOG
Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptive methods. The major advantage of LARCs compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term, effective use. In addition, after the device is removed, the return of fertility is rapid. Join Dr. David Eisenberg has he discusses when LARCs should be recommended as a first-line contraceptive choice and when they should not. He further details how to approach a shared decision-making discussion with patients about their contraceptive options.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
Since the recording of this CME activity, the following updates have been published:
-
NAMS Position Statement on the Management of Osteoporosis in Postmenopausal Women
- Menopause. 2021;28(9):973-997.
-
Consensus Statement from the Bone Health and Osteoporosis Foundation, formerly known as the National Osteoporosis Foundation
- The Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis Int. 2022;33(10):2049-2102.
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: James B. Bussel, MD
Program Chairman:
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Ayman Al-Hendy, MD
GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Elizabeth Stewart, MD
Fertility preservation is a significant clinical concern for all women of reproductive age diagnosed with endometriosis or uterine fibroids (UF). Drs. Elizabeth Stewart and Lee Shulman discuss how the advent of GnRH antagonists is affecting how we approach these 2 conditions. Management trends are evolving beyond reflexive, prophylactic surgery, so are you ready to change with the times?
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient’s voice. Your clinical impact may be profound.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.
Host: Robert L. Coleman, MD, FACOG, FACS
Guest: Kathleen Moore, MD, MS
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Ayman Al-Hendy, MD
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
Host: Mitchell D. Creinin, MD
In-office delivery of sexual and reproductive healthcare (SRH) services was markedly restricted for 2 years during the COVID-19 pandemic. Now, in-office access to these services has begun to improve. What have we learned since 2020 that can prepare us for future periods of reduced access? Join Dr. Mitchell Creinin as he discusses SRH service strategies initiated during the pandemic that remain useful even in times of full in-office access.
Host: Jeffery D. Dunn, PharmD, MBA
Guest: Gary M. Owens, MD
Guest: Anita L. Nelson, MD
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Stephanie Martin, DO
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
Host: Neilanjan Nandi, MD
Guest: Jean-Frederic Colombel, MD
There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Neilanjan Nandi, MD
Guest: David T. Rubin, MD
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Patty Cason, RN, MS, FNP-BC
Guest: Joely Pritzker, RN, MS, FNP-C
Are you ready to apply the latest counseling techniques to address the contraceptive revolution?
Join nurse practitioners Patty Cason and Joely Pritzker as they briefly review the history of contraceptive counseling and then use case vignettes to illustrate how shared decision-making techniques will support the appropriate use of nonhormonal contraceptive options, such as the vaginal pH modulator (VPM).
Participating in this activity will ensure that you are ready to effectively counsel patients on their many options so that each patient’s reproductive and sexual health goals can be met.
Host: Rachel Caskey, MD, MAPP
Guest: Gwendolyn Ramirez
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
Host: David J. Portman, MD
Guest: Patty Cason, RN, MS, FNP-BC
Guest: David L. Eisenberg, MD, MPH, FACOG
Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Anita H. Clayton, MD
Guest: Nancy Byatt, DO
Guest: Jennifer L. Payne, MD
In this panel discussion, Drs. Anita Clayton, Jennifer Payne, and Nancy Byatt walk us through two clinical cases of postpartum depression. Listen in as they discuss optimal strategies to screen, diagnosis, and treat patients, as well as go over the newer class of medications specifically targeted at treating PPD.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Anna-Barbara Moscicki, MD
Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Jeffrey T. Jensen, MD, MPH
The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lincoln Nadauld, MD, PhD
Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Host: Loretta J. Nastoupil, MD
Guest: John P. Leonard, MD
Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.
Host: David L. Eisenberg, MD, MPH, FACOG
Guest: David J. Portman, MD
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
Host: Loretta J. Nastoupil, MD
Guest: Gilles Salles, MD
Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.
Host: Linda Bradley, MD
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
Host: Nanette F. Santoro, MD
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
Host: Loretta J. Nastoupil, MD
Guest: Matthew J. Matasar, MD
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
Host: Matthew R. Weir, MD
Guest: Gates B. Colbert, MD, FASN
Guest: Robert Toto, MD
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Host: Javed Butler, MD, MBA, MPH
Guest: Paul W. Armstrong, MD
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Barbara Dehn
Physicians continue to seek the safest and most effective formulations for combined hormonal contraceptives (CHCs). The goal is to ensure that the patient’s chosen option optimizes the many benefits of estrogen but also reduces its adverse events—particularly those that are cardiovascular and thromboembolic in nature. Lower estrogen concentrations do not always mean better; sometimes better means better. But just like in a game of beach limbo, we have to ask: How low can you go?
Join us as Dr. Lee Shulman and Barbara Dehn, a nurse practitioner with vast contraception counseling and prescribing experience, discuss the dynamics of a new, lower-strength estrogen with the potential for use in combined oral contraceptives.
Host: Joel L. Cohen, MD
The differences between biostimulators and dermal fillers are simple yet critically important to their safe and successful use. With the help of 2D animation, Dr. Joel Cohen presents different techniques to optimize results in patients and minimize the risk of adverse effects.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Host: Charles E. Geyer, Jr., MD, FACP
Guest: Hope S. Rugo, MD
Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.
In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.
Host: Joel L. Cohen, MD
Guest: Jason D. Bloom, MD
Dr. Joel Cohen and Dr. Jason Bloom discuss the importance of neuromodulator selection and accurate dosing for the glabella and upper face. Dr. Bloom takes us through a patient demonstration of optimal injection techniques and dosing while addressing strategies to minimize the risk for adverse events.
Host: Joel L. Cohen, MD
Guest: Carolyn I. Jacob, MD, FAAD
What does the future hold for aesthetics? The 4 four available neuromodulators share a similar mechanism of action and efficacy profiles, but they each have their own unique characteristics, and now an emerging agent is about to enter the scene. Dr. Joel Cohen and Dr. Carolyn Jacob discuss the subtle differences among neuromodulators and the importance of dosing for duration, specifically for the glabella and upper face. They also explore potential adverse events and strategies to minimize your patients’ risks.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrew M. Kaunitz, MD, FACOG
The estrogen component of combined oral contraceptives in part helps to suppress FSH and folliculogenesis, stabilizes the endometrium, minimizes unscheduled bleeding, and supports progestin activity. Nonetheless, there are downsides to estrogen, including an increased risk for cardiovascular and thromboembolic adverse events such as pulmonary embolism and deep vein thrombosis.
Join Drs. Lee Shulman and Andrew Kaunitz as they envision a better oral contraceptive—one formulated with a high NEST activity estrogen that has less potential to increase the risk of thromboembolic events while maintaining good cycle control.
Host: Andrew Alexis, MD, MPH
Guest: Linda Stein Gold, MD
Depression, anxiety, failure to thrive, unemployment, low self-esteem, and suicidal ideation. What could possibly be contributing to all of these consequences? The culprit is acne—didn’t expect that, did you? Hear from dermatologists Dr. Andrew Alexis and Dr. Linda Stein Gold as they discuss the proper assessment of acne, its location—particularly beyond the face—and the differences to keep in mind when assessing skin of color. Faculty also examine the role that selective retinoid therapies play in treating acne and preventing the development of both the physical and psychological scars associated with this condition.
Host: Prathima Setty, MD
Fertility preservation technologies have become more advanced and more accessible over the past several years. Joining host Dr. Prathima Setty to discuss current options for women to protect their fertility is Dr. Naveed Khan, Reproductive Endocrinology and Infertility Specialist in Leesburg, VA. Dr. Khan practices with Shady Grove Fertility, the nation's largest fertility center, and is also a member of the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine.